Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: The second-generation antipsychotic drug olanzapine is an effective pharmacological treatment for psychosis. However, use of the drug is commonly associated with a range of metabolic side effects, including glucose intolerance and insulin resistance. These symptoms have been accurately modelled in rodents. Methods: We compared the effects of 3 distinct classes of antidiabetic drugs, metformin (100 and 500 mg/kg, oral), rosiglitazone (6 and 30 mg/kg, oral) and glyburide (2 and 10 mg/kg, oral), on olanzapine-induced metabolic dysregulation. After acutely treating female rats with lower (7.5 mg/kg) or higher (15 mg/kg) doses of olanzapine, we assessed glucose intolerance using the glucose tolerance test and measured insulin resistance using the homeostatic model assessment of insulin resistance equation. Results: Both doses of olanzapine caused pronounced glucose dysregulation and insulin resistance, which were significantly reduced by treatment with metformin and rosiglitazone; however, glucose tolerance did not fully return to control levels. In contrast, glyburide failed to reverse the glucose intolerance caused by olanzapine despite increasing insulin levels. Limitations: We evaluated a single antipsychotic drug, and it is unknown whether other antipsychotic drugs are similarly affected by antidiabetic treatments. Conclusion: The present study indicates that oral hypoglycemic drugs that influence hepatic glucose metabolism, such as metformin and rosiglitazone, are more effective in regulating olanzapine-induced glucose dysregulation than drugs primarily affecting insulin release, such as glyburide. The current model may be used to better understand the biological basis of glucose dysregulation caused by olanzapine and how it can be reversed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Stephenne, X., Foretz, M., Taleux, N., van der Zon, G. C., Sokal, E., Hue, L., Viollet, B., & Guigas, B. (2011) · Diabetologia · doi:10.1007/s00125-011-2311-5 · Cited by 287
Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues
LeBrasseur, N. K., Kelly, M., Tsao, T.-S., Farmer, S. R., Saha, A. K., Ruderman, N. B., & Tomas, E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2005 · Cited by 276
Schizophrenia and physical health problems
Von Hausswolff‐Juhlin, Y., Bjartveit, M., Lindström, E., & Jones, P. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01309.x · Cited by 161
Treatment with antipsychotics and the risk of diabetes in clinical practice
Kessing, L. V., Thomsen, A. F., Mogensen, U. B., & Andersen, P. K. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076935 · Cited by 152
Cited by
Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system
Leung, J. Y. T., Barr, A. M., Procyshyn, R. M., Honer, W. G., & Pang, C. C. Y. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.04.003 · Cited by 163
Self-citationAgarwal, S. M., Panda, R., Costa-Dookhan, K. A., MacKenzie, N. E., Treen, Q. C., Caravaggio, F., Hashim, E., Leung, G., Kirpalani, A., Matheson, K., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01338-2 · Cited by 41
Barr, A. M., Wu, C. H., Wong, C., Hercher, C., Töpfer, E., Boyda, H. N., Procyshyn, R. M., Honer, W. G., & Beasley, C. L. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.10.010 · Cited by 26
Metadata
- Authors
- Boyda, H. N., Procyshyn, R. M., Tse, L., Hawkes, E., Jin, C. H., Pang, C. C. Y., Honer, W. G., & Barr, A. M.
- Venue
- Journal of Psychiatry and Neuroscience
- Publisher
- Canadian Science Publishing
- Published
- 2012-11
- Volume
- 37
- Issue
- 6
- Pages
- 407-415
- ISSN
- 1180-4882 (ISSN-L)
- 1488-2434
- OpenAlex
- W2167797472
- Cited by
- 55
- References
- 7
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.